MRKMerck Sharp & Dohme LLCFinished
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
Hodgkin Lymphoma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 203 (final count)
- Started
- Oct 18, 2022
- Main results expected
- Sep 3, 2025
- Fully finished
- Jan 8, 2026
- Results posted
- Sep 1, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival (PFS) Per Lugano Response Criteria as Assessed by Investigator
Measured over: Up to approximately 34 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05508867 · record last updated 2026-09-01 · checked 2026-11-09 15:47 UTC